MI-136 is primarily utilized in the field of medical research, particularly in the study of cancer therapies. It functions as a potent and selective inhibitor of the menin-MLL interaction, which is crucial in the development of certain types of leukemia, such as those involving mixed lineage leukemia (MLL) rearrangements. By disrupting this interaction, MI-136 effectively halts the proliferation of cancer cells, making it a promising candidate for targeted cancer treatment. Researchers are actively exploring its potential in preclinical studies to assess its efficacy and safety, with the aim of advancing it towards clinical trials for leukemia patients. Additionally, its mechanism of action provides valuable insights into the role of protein-protein interactions in cancer biology, contributing to the broader understanding of oncogenic processes.